Karen O'Hanlon Cohrt

Gene reporter assays have contributed hugely to our understanding of how genes are regulated during growth and development, for example, through the study of spatiotemporal gene expression patterns, as well as how gene expression is regulated by transcription factors, gene regulatory elements (so-called cis-acting elements), and exogenous regulators (trans-acting factors).

Cancer is a complex and dynamic disease that is often very challenging to treat. Patients with the same cancer type often respond differently to the same chemotherapy regime, and oncologists don’t yet have the tools to predict the optimal treatment for each individual patient. However, with the latest advances in engineered tumour models, patient-specific or personalised cancer treatment is likely to become a reality.

In the world of drug discovery, target can mean something different depending on whom you ask. It may refer to the intended market for the drug (e.g., developing countries), the therapeutic indications (i.e. what condition(s) the drug is expected to treat), the biological pathway or process that the drug modulates, or the molecular recognition site to which it binds.

According to John LaMattina in Forbes last year, more and more senior scientific executives are moving from pharma to small biotechs or startup initiatives. While the jury is out on whether this observation reflects a real trend or not, we at Labiotech are keen to learn about what drives people to make such a move!

Osteoblasts, often referred to as bone-forming cells, are specialized and terminally differentiated products of mesenchymal stem cells whose major function is to synthesize bone in a process known as osteogenesis.

The world of drug discovery is rife with new approaches within immunotherapy, personalized vaccines, microbiome therapies, and CRISPR-based therapies in an attempt to provide novel treatments and cures for a wide range of diseases, most often cancer. Despite progress in these areas, with FDA-approval granted for the first two CAR T-cell therapies in 2017, more than 90 % of the drugs currently available on the worldwide therapeutic market is comprised of small molecules. Image Credit: e-Magine Art (https://bit.ly/2Lnxjte)

Organoids are in vitro-derived miniaturized organs that exhibit self-organization and recapitulate the functions of the in vivo organ they represent. For organoids to mimic their real-life counterparts as much as possible, they must receive appropriate physical and biochemical cues.

Mesenchymal cells (MSCs) are rapidly gaining traction in cancer therapy. Although they are not the only stem cells with anti-cancer activity, MSCs are often preferred because of their low immunogenicity and inherent ability to migrate to tumor sites. So far, numerous attempts have been made to load MSCs with therapeutic proteins, oncolytic viruses, chemotherapeutic drugs or nanoparticles bearing anti-cancer drugs, with some very promising results. Let’s take a look at some of the advances in this area to date! Image Credit: londoncalling2001 (https://bit.ly/2JRWck4)

Today is the First International NASH Day, and to mark the occasion, we bring you an update on Europe’s efforts to tackle this largely unrecognized liver disease that currently has no treatment and affects almost 12% of the adult population in developed countries worldwide.

Image Credit: Lung-on-a-chip: National Center for Advancing Translational Sciences (https://bit.ly/2Jbv1Qg ) Cancer organoids are generated from cells donated by cancer patients. Their major applications lie in their potential to shed light on the processes of cancer development and metastasis, to help us understand heterogeneity within tumors via single cell sequencing, and to direct clinicians towards personalized cancer treatments based on patient-specific drug testing.

By the 30th of March 2019, the UK will officially exit the EU, in a move that is popularly known as Brexit. With this date fast approaching, companies, organizations and individuals all over the world have speculated about how Brexit might impact them. In this article, I take a broader look at how Brexit could impact European biotech in the future.

We gave you an introduction to mesenchymal cells (MSCs) in one of our earlier Cell of the Month posts. Staying with the theme of recapitulating in vivo development processes (check out our most recent post on organoids), we wanted to take a closer look at MSCs and their two applications that have attracted most attention to date – cellular therapies and research models. Cover Image: https://bit.ly/2jnTbs9

Biologicals have completely changed the way we treat diseases, and their growth has exploded in the last two decades. Not surprisingly, they took a whopping 7 out of 15 spots on the list of 2017’s best selling drugs globally. We were of course keen to find out how European-derived drugs faired out in this list. Remarkably, almost half of the top 10 best-selling drugs worldwide come from Europe!

In the modern fast-paced worlds of research and medicine, disease models that take us closer to the real-life situation are highly desirable. While we can’t discredit the power of in vitro cell culture methods to provide important clues about biological processes, mechanisms of disease, and response to drugs, the availability of life-like tissue systems such as organoids provides obvious opportunities to study these aspects of human biology in a much more realistic manner. Image Credit: Yale Rosen (http://bit.ly/2I306Cf)

In multicellular organisms e.g., humans, other animals, and plants, almost every cell contains identical genetic information. However, not all cell types behave in the same way. For example, white blood cells are distinct from bone cells in appearance and function. Chromatin is a dense complex found in the nucleus of the cell that contains the majority of our DNA, along with RNA and associated proteins. It plays a critical role in establishing and maintaining these intracellular differences (or

In one of our recent posts, we addressed the types of genetic variability that exist in humans and why a greater understanding of these is critical in diagnostics, for predicting our response to new drugs, and in the development of personalized treatments. Here, we will look at how genetic variability can serve as a tool to expand our understanding of disease susceptibility and mechanisms, using schizophrenia as a case study. Image Credit: Mark Turnauckas

Alzheimer’s disease (AD) is the sixth leading cause of death in the United States (US), where it is directly responsible for more than 500,000 deaths each year. Worldwide, approximately 44 million people live with AD, and with an ageing population, this number is expected to rise significantly over the next three decades.

Most of us were introduced to phagocytosis as a cellular event where dead host cells, microbial cells or their components, or other foreign bodies are engulfed and often destroyed by specialized cells known as phagocytes. During my undergraduate studies, phagocytosis was a small topic within immunology and macrophages were the crème de la crème of phagocytes, patrolling the body’s tissues for foreign invaders, much like security guards patrolling their territories.

Coastal marine ecosystems represent the most diverse and productive parts of the world’s oceans, providing a range of crucial ecosystem services such as food, protection, and recreation to humankind. Unfortunately, coastal ecosystems are threatened due to marine climate change, marked by three related and concomitant oceanic changes: warming, acidification (increased carbon dioxide levels), and declining oxygen levels.

Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, is a serious cause of disease and mortality worldwide, especially in developing countries. Co-infection with the human immunodeficiency virus (HIV) aggravates this situation, and puts intense pressure on national healthcare services in sub-Saharan Africa, where up to 80% of TB patients are HIV-infected, and where TB is now the leading cause of death in HIV-infected individuals.